Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial

Giovannella Palmieri, Carlo Buonerba, Margaret Ottaviano, Piera Federico, Filomena Calabrese, Claudia Von Arx, Ana Paula De Maio, Mirella Marino, Maurizio Lalle, Liliana Montella, Carmela Merola, Michele Milella, Marina Bergaglio, Giuseppe Di Lorenzo, Vincenzo Damiano

Research output: Contribution to journalArticlepeer-review


Background: A multi-institutional Phase II trial was initiated in 2005 to test the combination gemcitabine and capecitabine in patients with thymic epithelial malignancies (TETs). Patients & methods: Patients with histologic confirmation of TET diagnosis by central review who had received >1 systemic chemotherapy treatment were included. Patients received oral capecitabine (650 mg/mq twice daily on days 1-14) and intravenous gemcitabine (1000 mg/mq on days 1 and 8 every 3 weeks). Results: Of the 30 patients included (18 men, 12 women; median age: 57 years, range: 48-61 years), the majority (73%) had thymoma, and the remaining thymic carcinoma. Eight patients developed grade 3-4 neutropenia. A total of 12 patients had a response. Median progression-free survival was 11 months (range: 6.5-16.5). Conclusion: Capecitabine and gemcitabine is highly active in TETs.

Original languageEnglish
Pages (from-to)2141-2147
Number of pages7
JournalFuture Oncology
Issue number14
Publication statusPublished - Nov 1 2014


  • capecitabine
  • gemcitabine
  • thymic epithelial tumors
  • thymomas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)


Dive into the research topics of 'Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial'. Together they form a unique fingerprint.

Cite this